0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Siglec-15

Siglec-15

Brief Information

Name:Sialic acid-binding Ig-like lectin 15
Target Synonym:SIGLEC15,Sialic Acid Binding Ig Like Lectin 15,CD33 Antigen-Like 3,CD33L3,Sialic Acid-Binding Ig-Like Lectin 15,SIGLEC-15,HsT1361,CD33 Molecule-Like 3,Sialic Acid Binding Ig-Like Lectin 15
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:2
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

Part of Bioactivity data

SG5-H82F5-Cell-based assay
Human FcRn Heterodimer Protein Cell_Base

Biotinylated Human Siglec-15, Fc,Avitag (Cat. No. SG5-H82F5) inhibits Anti-CD3-induced proliferation of PBMC. The ED50 for this effect is 0.48-0.57 μg/mL (Routinely tested).

SG5-H5253-Cell-based assay
Human FcRn Heterodimer Protein Cell_Base

Human Siglec-15, Fc Tag (Cat. No. SG5-H5253) inhibits Anti-CD3-induced proliferation of PBMC. The ED50 for this effect is 0.46-0.54 μg/mL (Routinely tested).

SG5-H5253-SPR
Human_FcRn_Heterodimer_Protein_SPR

Immobilized Neu5Ac(a2-6)GalNAc-PAA-biotin on SA Chip can bind Human Siglec-15, Fc Tag (Cat. No. SG5-H5253) with an affinity constant of 4.49 μM as determined in a SPR assay (Biacore T200) (Routinely tested).

SG5-C5253-BLI
Human_FcRn_Heterodimer_Protein_Bli

Loaded Cynomolgus Siglec-15, Fc Tag (Cat. No. SG5-C5253) on ProteinA Biosensor, can bind Neu5Ac(a2-6)GalNAc-PAA-biotin with an affinity constant of 0.62 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Customer Reviews

Synonym Name

CD33 antigen-like 3,SIGLEC-15,CD33L3,sialic acid-binding Ig-like lectin 15,Siglec15,Siglec-15

Background

Siglec-15 is a DAP12-associated immunoreceptor, which belongs to the immunoglobulin superfamily and SIGLEC (sialic acid binding Ig-like lectin) family. Siglecs are cell surface proteins that bind sialic acid. They are found primarily on the surface of immune cells and are a subset of the I-type lectins. Siglec-15 consisting of immunoglobulin (Ig)-like domains, transmembrane domain and a short cytoplasmic tail. Siglec-15 is that recognizes sialylated glycans and regulates osteoclast differentiation. Siglec-15 is a potential therapeutic target for osteoporosis and plays a conserved regulatory role in the immune system of vertebrates.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
NC-318 5G-12; NC-318 Phase 2 Clinical Yale School Of Medicine Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Carcinoma, Non-Small-Cell Lung Details
DS-1501 DS-1501 Phase 1 Clinical Daiichi Sankyo Co Ltd Osteoporosis Details

This web search service is supported by Google Inc.

totop